ENTITY
Bristol Myers Squibb Co

Bristol Myers Squibb Co (BMY US)

236
Analysis
Health CareUnited States
Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
more
25 Jan 2019 08:40Syndicated

Bristol Myers Squib – Reaffirming Its View on Celgene Corp

The management of Bristol Myers Squibb Co (BMY US) reiterated its optimistic view regarding the acquisition of Celgene Corp (CELG US) on its Q4-18...

Logo
527 Views
Share
bullishXiaomi Corp
20 Jan 2019 09:16

Last Week in Event SPACE: Xiaomi, NTT, Capitaland, Panalpina, Celgene/Bristol Myers, Amorepacific

Last Week in Event SPACE ... Do not buy Xiaomi Corp (1810 HK) as there is a LOT of overhang still to come.  Indications are a total of ¥550-650bn...

Logo
1k Views
Share
18 Jan 2019 11:41Syndicated

Celgene and Bristol-Myers Squibb – Undervalued and Underappreciated

A dismal 2018 for the pharmaceutical and bio-tech stocks seems far in the rear view mirror. 2019 began with a bang with two blockbuster deals in...

Logo
689 Views
Share
bullishCelgene Corp
13 Jan 2019 14:01

Celgene Acquisition by Bristol-Myers Squibb: A Call to Arbs

On January 3, 2019, Bristol Myers Squibb Co (BMY US) and Celgene Corp (CELG US) announced a definitive agreement for BMY to acquire Celgene in a...

Logo
854 Views
Share
18 Dec 2018 17:35

Taisho Frontrunner to Acquire BMS’s French OTC Business

Event – Bristol Myers Squibb Co (BMY US)'s  French OTC business UPSA has been on the block since June 2018. According to a December 17, 2018...

x